$LPTX
LEAP THERAPEUTICS, INC.

2024 Q4 Form 10-Q Financial Statement

#000141057824001913 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.940M
YoY Change -11.71%
% of Gross Profit
Research & Development $14.92M
YoY Change 29.66%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $17.86M
YoY Change 20.37%
Operating Profit -$17.86M
YoY Change 20.37%
Interest Expense $886.0K
YoY Change 52.76%
% of Operating Profit
Other Income/Expense, Net -$499.0K
YoY Change -190.73%
Pretax Income -$17.47M
YoY Change 27.5%
Income Tax $708.0K
% Of Pretax Income
Net Earnings -$18.18M
YoY Change 32.71%
Net Earnings / Revenue
Basic Earnings Per Share -$0.44
Diluted Earnings Per Share -$0.44
COMMON SHARES
Basic Shares Outstanding 38.32M 38.26M
Diluted Shares Outstanding 41.21M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.82M
YoY Change -22.15%
Cash & Equivalents $62.82M
Short-Term Investments
Other Short-Term Assets $209.0K
YoY Change -30.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $63.81M
YoY Change -21.95%
LONG-TERM ASSETS
Property, Plant & Equipment $370.0K
YoY Change 4011.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $865.0K
YoY Change -3.89%
Total Long-Term Assets $1.235M
YoY Change -3.89%
TOTAL ASSETS
Total Short-Term Assets $63.81M
Total Long-Term Assets $1.235M
Total Assets $65.05M
YoY Change -21.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.946M
YoY Change 0.8%
Accrued Expenses $9.049M
YoY Change 89.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.09M
YoY Change 45.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $16.09M
Total Long-Term Liabilities $0.00
Total Liabilities $16.09M
YoY Change 45.8%
SHAREHOLDERS EQUITY
Retained Earnings -$451.9M
YoY Change 16.75%
Common Stock $38.00K
YoY Change 46.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.95M
YoY Change
Total Liabilities & Shareholders Equity $65.05M
YoY Change -21.67%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$18.18M
YoY Change 32.71%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$15.60M
YoY Change 48.85%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -66.00K
YoY Change
NET CHANGE
Cash From Operating Activities -15.60M
Cash From Investing Activities
Cash From Financing Activities -66.00K
Net Change In Cash -15.67M
YoY Change 49.48%
FREE CASH FLOW
Cash From Operating Activities -$15.60M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001509745
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25565414
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38264464
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37990
dei Entity Registrant Name
EntityRegistrantName
LEAP THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4412575
dei Entity Address Address Line1
EntityAddressAddressLine1
47 Thorndike St, Suite B1-1
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
714-0360
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LPTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38317897
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62823000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70643000
CY2024Q3 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
780000
CY2023Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
771000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
209000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
183000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
63812000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
71597000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
370000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
257000
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
865000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
966000
CY2024Q3 us-gaap Assets
Assets
65047000
CY2023Q4 us-gaap Assets
Assets
72825000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5946000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6465000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9049000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5957000
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
722000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
376000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
262000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16093000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12684000
CY2024Q3 us-gaap Liabilities
Liabilities
16093000
CY2023Q4 us-gaap Liabilities
Liabilities
12684000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38264464
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25565414
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
38000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
500850000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
459591000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
106000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-451940000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-399582000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
48954000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
60141000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65047000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72825000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14915000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11503000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44099000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61549000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2940000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3330000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9833000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10672000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
17855000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
14833000
us-gaap Operating Expenses
OperatingExpenses
53932000
us-gaap Operating Expenses
OperatingExpenses
72221000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17855000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14833000
us-gaap Operating Income Loss
OperatingIncomeLoss
-53932000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72221000
CY2024Q3 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
894000
CY2023Q3 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
1084000
lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
2534000
lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
3089000
CY2024Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
-499000
CY2023Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
554000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1124000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-501000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-18000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-953000
lptx Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
12000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17468000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13696000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51416000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68949000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
708000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
708000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18176000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13696000
us-gaap Net Income Loss
NetIncomeLoss
-52124000
us-gaap Net Income Loss
NetIncomeLoss
-68949000
us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
234000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18176000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13696000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-52358000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-68949000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.78
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41209639
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41209639
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26987182
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26987182
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36307890
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36307890
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18240455
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18240455
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18176000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13696000
us-gaap Net Income Loss
NetIncomeLoss
-52124000
us-gaap Net Income Loss
NetIncomeLoss
-68949000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
346000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-100000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
632000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18173000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13350000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52224000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68317000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
84057000
CY2023Q3 lptx Fractional Value Paid In Cash
FractionalValuePaidInCash
1000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
346000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1300000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13696000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
72008000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58866000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
9805000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13000
lptx Adjustments To Additional Paid In Capital Redemption Of Warrants
AdjustmentsToAdditionalPaidInCapitalRedemptionOfWarrants
29000
lptx Conversion Of Temporary Equity Into Permanent Equity Value
ConversionOfTemporaryEquityIntoPermanentEquityValue
67715000
lptx Adjustments To Additional Paid In Capital Reclassification Of Warrants To Equity
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
78000
lptx Fractional Value Paid In Cash
FractionalValuePaidInCash
2000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
632000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3875000
us-gaap Net Income Loss
NetIncomeLoss
-68949000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
72008000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
65788000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1339000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18176000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
48954000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
60141000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
lptx Stock Issuance Costs
StockIssuanceCosts
2948000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37051000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-100000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3957000
us-gaap Net Income Loss
NetIncomeLoss
-52124000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
48954000
us-gaap Profit Loss
ProfitLoss
-52124000
us-gaap Profit Loss
ProfitLoss
-68949000
lptx In Process Research And Development Costs Acquired In Connection With Acquisition Of Flame
InProcessResearchAndDevelopmentCostsAcquiredInConnectionWithAcquisitionOfFlame
29582000
us-gaap Depreciation
Depreciation
5000
us-gaap Depreciation
Depreciation
11000
us-gaap Share Based Compensation
ShareBasedCompensation
3957000
us-gaap Share Based Compensation
ShareBasedCompensation
3875000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-18000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-953000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-83000
lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
-1279000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2573000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1006000
lptx Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-307000
lptx Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-306000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
708000
lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-307000
lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-308000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-100000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-801000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44787000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33373000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
50362000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1393000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48969000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
39999000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2948000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
29000
lptx Payment Of Fractional Shares
PaymentOfFractionalShares
1000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37080000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-30000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-113000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-323000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7820000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15243000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70643000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65500000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62823000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80743000
lptx Remeasurement Of Right Of Use Asset And Lease Liability
RemeasurementOfRightOfUseAssetAndLeaseLiability
420000
us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
234000
lptx Issuance And Conversion Of Temporary Stock Connection With Acquisition
IssuanceAndConversionOfTemporaryStockConnectionWithAcquisition
-67715000
lptx Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
78000
lptx Issuance Of Common Stock In Connection With Acquisition
IssuanceOfCommonStockInConnectionWithAcquisition
9805000
lptx Issuance Of Warrants For Purchase Of Common Stock In Connection With Acquisition
IssuanceOfWarrantsForPurchaseOfCommonStockInConnectionWithAcquisition
13000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
928000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62823000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-451940000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-52358000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62823000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The presentation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2023 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2024Q3 lptx Research And Development Incentive Receivable Current And Noncurrent
ResearchAndDevelopmentIncentiveReceivableCurrentAndNoncurrent
780000
CY2023Q4 lptx Research And Development Incentive Receivable Current And Noncurrent
ResearchAndDevelopmentIncentiveReceivableCurrentAndNoncurrent
771000
CY2024Q3 lptx Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
499000
CY2023Q3 lptx Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
554000
lptx Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
1124000
lptx Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
0
CY2022Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
2099000
CY2023 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
2333000
CY2023 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1101000
CY2023 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-96000
CY2023Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
771000
lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
9000
CY2024Q3 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
780000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents. All cash and cash equivalents are held in United States or Australian financial institutions and money market funds. At times, the Company may maintain cash balances in excess of the federally insured amount of $250 per depositor, per insured bank, for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the year ended December 31, 2023 or for the nine months ended September 30, 2024.</p>
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25018000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
25018000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
39065000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
39065000
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25018000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
39065000
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12000
CY2024Q3 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
6193000
CY2023Q4 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2522000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
138000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
254000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2718000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3181000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9049000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5957000
lptx Operating Lease Additional Liability
OperatingLeaseAdditionalLiability
420000
lptx Operating Lease Additional Right Of Use Asset
OperatingLeaseAdditionalRightOfUseAsset
420000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
370000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
376000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
115000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
113000
us-gaap Operating Lease Cost
OperatingLeaseCost
340000
us-gaap Operating Lease Cost
OperatingLeaseCost
341000
CY2024Q3 lptx Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
346000
CY2023Q3 lptx Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
339000
lptx Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
117000
lptx Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
113000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
117000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
273000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
390000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
376000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6531548
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12000
lptx Number Of Vote On Common Shares
NumberOfVoteOnCommonShares
1
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3384366
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.97
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3431000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1727500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10557
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
254674
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.69
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4846635
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M26D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
527000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2396563
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4846635
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M26D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
527000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9299
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0398
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5633000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y11M4D
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18176000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13696000
us-gaap Net Income Loss
NetIncomeLoss
-52124000
us-gaap Net Income Loss
NetIncomeLoss
-68949000
us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
234000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18176000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18176000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13696000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13696000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-52358000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-52358000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68949000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-68949000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41209639
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41209639
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26987182
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26987182
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36307890
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36307890
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18240455
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18240455
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.78
lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
2945175
CY2023Q3 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
2945175
lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
2945175
CY2024Q3 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
2945175
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8660508
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7297018
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8660508
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7297018
CY2024Q3 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
65000
CY2024Q3 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
0
CY2024Q3 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
0
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
708000
CY2024Q3 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
708000
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001913-index-headers.html Edgar Link pending
0001410578-24-001913-index.html Edgar Link pending
0001410578-24-001913.txt Edgar Link pending
0001410578-24-001913-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lptx-20240930.xsd Edgar Link pending
lptx-20240930x10q.htm Edgar Link pending
lptx-20240930xex31d1.htm Edgar Link pending
lptx-20240930xex32d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lptx-20240930_cal.xml Edgar Link unprocessable
lptx-20240930x10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lptx-20240930_def.xml Edgar Link unprocessable
lptx-20240930_lab.xml Edgar Link unprocessable
lptx-20240930_pre.xml Edgar Link unprocessable